Nyrada – European Patent to be Granted for Cholesterol-Lowering Drug
The European Patent Office has issued a Notice of Intention to grant Nyrada’s patent application for novel compounds inhibiting PCSK9…. Read more
The European Patent Office has issued a Notice of Intention to grant Nyrada’s patent application for novel compounds inhibiting PCSK9…. Read more
Highlights: • Brain Injury Program: – Exploratory study shows new lead drug candidate NYR-BI02 could be taken orally, offers potential… Read more
Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation ahead of a… Read more
Nyrada Inc. (ASX: NYR) released an announcement about its new lead brain injury drug candidate NYR-BI02. The new drug shows… Read more
Highlights: • Research and development costs of $1.13M as Nyrada’s lead preclinical programs advance (1H FY2021: $1.05M) • Robust cash… Read more
Highlights: • Cholesterol-Lowering Program: – Charles River Laboratories appointed to conduct safety pharmacology and toxicology studies in Nyrada’s cholesterol-lowering drug… Read more
This morning Nyrada provided an update on their brain injury program. The company is currently undertaking a pilot study to… Read more
Nyrada (ASX:NYR) has provided an update to the market regarding its cholesterol lowering drug program which is due to enter… Read more